Skip to content

FeMoropopliteal AngioSculpt™ SCoring BallOon CaTheter Study

Prospective, Multicenter, Non-randomized Clinical Trial Investigating the Safety and Efficacy of the AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for the Treatment of Femoropopliteal Stenotic Disease.

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00619788
Acronym
MASCOT
Enrollment
50
Registered
2008-02-21
Start date
2008-03-31
Completion date
2009-10-31
Last updated
2010-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Occlusive Disease

Brief summary

This investigation is designed to demonstrate the efficacy and safety of the 4.0-5.0mm AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for femoropopliteal use in a controlled clinical investigation. The scoring balloon is a semi-compliant balloon encircled by 3 spiral struts with a nitinol scoring element, which theoretically provides targeted scoring of lesions, by concentrating the dilation force thus minimizing barotrauma, elastic recoil and uncontrolled dissection. This may improve the outcome of the intervention and reduce the number of stents required.

Interventions

DEVICE4.0-5.0mm AngioSculpt Scoring Balloon Catheter

The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.

Sponsors

AngioScore, Inc.
CollaboratorINDUSTRY
Flanders Medical Research Program
Lead SponsorNETWORK

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Stenotic (\>50%) or occlusive atherosclerotic disease of the femoropopliteal arteries (primarily superficial femoral arteries - SFA) * Length of lesion \>5 cm or 2 times the AngioSculpt balloon length (whichever is longer) * Reference vessel diameter should be 4.0-6.0 mm * Life altering claudication or critical limb ischemia (Rutherford 3-5) * No untreated inflow-limiting arterial lesions * At least single vessel run-off until the ankle * The patient must be \> 18 years. * Life-expectancy of more than 12 months * The subject or legal guardian has been informed of the nature of the evaluation; agrees to its provisions and has signed informed consent * The patient is capable to follow all evaluation requirements.

Exclusion criteria

* Patient refusing treatment * The reference segment diameter is not suitable for available catheter design * Length of lesion is ≥5 cm or requires more than two overlapping AngioSculpt balloon inflations (whichever is longer) to cover the entire lesion (however, more than two inflations are permitted within an acceptable lesion length) * The patient has a known allergy to heparin, aspirin or other anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies * The patient has a history of prior life-threatening contrast media reaction * The patient is currently enrolled in another investigational device or drug trial * The patient is currently breast-feeding, pregnant or intends to become pregnant

Design outcomes

Primary

MeasureTime frame
Complication Free Survival at 1 month post-procedure (complications = major amputations defined as amputations at or above the ankle, any cause of death and TLR)1 month

Secondary

MeasureTime frame
patency of the target lesion. Primary patency is defined as the absence of: a) target lesion revascularization (TLR); b) major amputation due to lesion restenosis or occlusion; c) conversion to bypass surgery and d) untreated significant stenosis on CFDU12 months

Countries

Belgium, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026